---
title: "Quetiapine - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db01224-mesh-d012559-1.html
toc: false 
---


Path ID: `DB01224_MESH_D012559_1`
{% include image.html url="images/db01224-mesh-d012559-1.png" file="db01224-mesh-d012559-1.png" alt="db01224-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D000069348">MESH:D000069348 </a> | quetiapine | Drug |
| <a href="https://identifiers.org/UniProt:P28223">UniProt:P28223 </a> | 5-hydroxytryptamine receptor 2A | Protein |
| <a href="https://identifiers.org/UniProt:P14416">UniProt:P14416 </a> | D(2) dopamine receptor | Protein |
| <a href="https://identifiers.org/GO:0014046">GO:0014046 </a> | dopamine secretion | BiologicalProcess |
| <a href="https://identifiers.org/CHEBI:18243">CHEBI:18243 </a> | dopamine | ChemicalSubstance |
| <a href="https://identifiers.org/UBERON:0009834">UBERON:0009834 </a> | dorsolateral prefrontal cortex | GrossAnatomicalStructure |
| <a href="https://identifiers.org/UBERON:0001910">UBERON:0001910 </a> | medial forebrain bundle | GrossAnatomicalStructure |
| <a href="https://identifiers.org/HP:0100543">HP:0100543 </a> | Cognitive impairment | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0030213">HP:0030213 </a> | Emotional blunting | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0012154">HP:0012154 </a> | Anhedonia | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0002465">HP:0002465 </a> | Poor speech | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0000741">HP:0000741 </a> | Apathy | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0000709">HP:0000709 </a> | Psychosis | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D012559">MESH:D012559 </a> | Schizophrenia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Quetiapine | DECREASES ACTIVITY OF | D(2) Dopamine Receptor |
| Quetiapine | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 2A |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY REGULATES | Dopamine Secretion |
| D(2) Dopamine Receptor | POSITIVELY REGULATES | Dopamine Secretion |
| Dopamine Secretion | INCREASES ABUNDANCE OF | Dopamine |
| Dopamine | LOCATED IN | Medial Forebrain Bundle |
| Medial Forebrain Bundle | CORRELATED WITH | Psychosis |
| Psychosis | POSITIVELY CORRELATED WITH | Schizophrenia |
| Dopamine | LOCATED IN | Dorsolateral Prefrontal Cortex |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Cognitive Impairment |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Emotional Blunting |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Anhedonia |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Poor Speech |
| Dorsolateral Prefrontal Cortex | CORRELATED WITH | Apathy |
| Cognitive Impairment | POSITIVELY CORRELATED WITH | Schizophrenia |
| Emotional Blunting | POSITIVELY CORRELATED WITH | Schizophrenia |
| Anhedonia | POSITIVELY CORRELATED WITH | Schizophrenia |
| Poor Speech | POSITIVELY CORRELATED WITH | Schizophrenia |
| Apathy | POSITIVELY CORRELATED WITH | Schizophrenia |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB01224#mechanism-of-action](https://go.drugbank.com/drugs/DB01224#mechanism-of-action)
  - [https://go.drugbank.com/drugs/DB01224#BE0000451](https://go.drugbank.com/drugs/DB01224#BE0000451)
  - [https://go.drugbank.com/drugs/DB01224#BE0000756](https://go.drugbank.com/drugs/DB01224#BE0000756)
